Multiple Sclerosis Clinical Trials in San Antonio

Showing 361-380 of 513 trials

COMPLETEDPhase 1< 1 mile

BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

NCT00962611

The purpose of this study is to determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.

Neoplasms

Bayer57 participantsStarted Nov 2009

Scottsdale, Arizona, United States • Pittsburgh, Pennsylvania, United States • San Antonio, Texas, United States

COMPLETEDPhase 2< 1 mile

Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

NCT00335556

This phase II trial is studying how well combination chemotherapy, radiation therapy, and/or surgery work in treating patients with high-risk kidney tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Childhood Renal Cell CarcinomaClear Cell Renal Cell CarcinomaClear Cell Sarcoma of the Kidney+10 more

Children's Oncology Group291 participantsStarted Jun 2006

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Mobile, Alabama, United States +184 more locations

BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

Multiple Sclerosis Trials in Other Cities

An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

Combined Behavioral and Drug Treatment of Overactive Bladder in Men

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

Natalizumab Re-Initiation of Dosing

Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis

Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

ARI103094-Follow-Up Study for REDUCE Study Subjects

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

PRESERVE-Zenith® Iliac Branch System Clinical Extended Study

Evolution® Biliary Stent System-Fully Covered

Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

Other Conditions in San Antonio